

CMP: ₹ 700

Target: ₹ 865 (24%)

Target Period: 12 months

February 14, 2023

BUY



US momentum drives growth; LatAm steady...

About the stock: Caplin derives almost entire revenues through exports with 86% of revenues from Emerging Markets (LatAm + RoW) where it has an end-to-end business model through last mile logistical solutions for its exclusive distributors.

- In the US, overall development pipeline remains robust, with 58+ ANDAs under development with an addressable market in US at over US\$5 billion
- For LatAm markets, it outsources ~45% of products (China: 30%; Indian vendors:70%) and in-house manufacturing remains at ~55%
- Caplin Steriles caters to the rapidly growing demand for injectable products in the US and other regulated markets

Q3FY23 Results: In line numbers with better-than-expected US growth.

- Revenues grew 14% YoY to ₹ 372 crore propelled by the US also growing ~99% YoY to ₹ 62 crore. LatAm & RoW growth was steady at 7% YoY
- EBITDA grew 7.3% YoY to ₹ 108.3 crore and margins declined 184 bps YoY to 29.1%
- Adjusted PAT grew 28.6% YoY to ₹ 96.4 crore

What should investors do? Caplin's share price has grown at 27.82% CAGR over the past three years.

- Maintain **BUY** due to 1) Steady growth from legacy LatAm markets and increasing footprints in other geographies, 2) Traction from visible order book in the US and 3) Calculated capex decisions to expand capacity, widen portfolio and backward integration

Target Price and Valuation: Valued at ₹ 865 i.e. 16x P/E on FY25E EPS of ₹ 54.1.

Key triggers for future price performance:


- Execution of the ~₹ 450-500 crore capex towards Caplin Steriles, RoW facility, oncology (OSD & injectable) project and API backward integration
- Growth momentum to persist mainly due to further expansion in front end, increasing product basket, change in product mix, launching of own brands
- Plans to expand in six major markets of the US, Mexico, Brazil, Europe, South Africa and CIS countries with differentiated strategies

Alternate Stock Idea: Apart from Caplin, in our coverage, we like Granules.

- Granules India is a vertically integrated company that manufactures API, intermediates and finished dosages
- BUY with a target price of ₹ 355

Particulars	
Particular	Amount
Market Capitalisation	₹ 5320 crore
Debt (FY22)	₹ 2 crore
Cash (FY22)	₹ 463 crore
EV	₹ 4859 crore
52 week H/L	857/626
Equity capital	₹ 15.2 crore
Face value	₹ 2

Shareholding pattern				
(in %)	Mar-22	Jun-22	Sep-22	Dec-22
Promoter	68.9	68.9	68.9	68.8
Others	31.1	31.1	31.1	31.2



- Recent Event & Key risks**
- Received approval for Carboprost Tromethamine Injection USP from USFDA.
 - Key Risk:** (i) Regulatory hurdles (ii) Slower ramp-up in new markets

Research Analyst
 Siddhant Khandekar
 siddhant.khandekar@icicisecurities.com
 Kushal Shah
 kushal.shah@icicisecurities.com
 Utkarsh Jain
 utkarsh.jain@icicisecurities.com

Key Financial Summary

Key Financials (₹ Crore)	FY21	FY22	5 year CAGR (FY17-22)	FY23E	FY24E	FY25E	2 year CAGR (FY23E-25E)
Revenues	1061.3	1269.4	25.9	1456.9	1659.0	1865.3	13.1
EBITDA	328.7	394.7	26.0	429.0	493.6	564.2	14.7
EBITDA Margins (%)	31.0	31.1		29.4	29.8	30.3	
Net Profit	242.3	299.8	25.7	371.1	363.7	411.3	5.3
EPS (Adjusted)	31.9	39.5		48.8	47.9	54.1	
PE (x)	22.0	17.7		14.3	14.6	12.9	
RoCE (%)	25.4	25.3		23.5	22.4	21.6	
RoE (%)	20.4	20.2		20.2	16.7	16.0	

Source: Company, ICICI Direct Research

Key takeaways of recent quarter & conference call highlights

Q3FY23: In line numbers, US momentum continues

- Revenues grew 14% YoY to ₹ 372 crore propelled by LatAm & RoW growing 6.6% YoY and US also growing 98.8% YoY. EBITDA grew 7.3% YoY to ₹ 108.3 crore whereas EBITDA margins declined 184 bps YoY to 29.1%. Adjusted PAT grew 28.6% YoY to ₹ 96.4 crore
- The company's softgel and injectable businesses both continue to increase in terms of sales and profitability. Increased sales in US markets were primarily related to incremental share from current products. With multiple orders received this quarter, Caplin Steriles continued its expansion into newer geographies, including Turkmenistan, Uzbekistan, Vietnam, Cambodia, and the Philippines. Caplin Steriles completed exhibit batches of four complex injectable/ophthalmic products, to be filed in the US and global markets within 2023. Thus, banking on strong footprint in the smaller LatAm markets, the company is establishing itself in the complex US injectable space besides foraying into bigger LatAm markets. We are positive on the company's strong earnings profile and focused approach with growth capex

Exhibit 1: Variance Analysis

	Q3FY23	Q3FY22	Q2FY23	YoY (%)	QoQ (%)	Comments
Revenue	372.0	326.2	359.1	14.0	3.6	Revenues grew 14% YoY to ₹ 372 crore propelled by Latin America & RoW growing 6.6% YoY and US also growing 98.8 % YoY
Raw Material Expenses	163.9	143.8	165.5	13.9	-1.0	
Gross margins (%)	55.9	55.9	53.9	4 bps	203 bps	
Employee Expenses	35.5	29.4	34.0	21.0	4.5	
Other Expenditure	64.3	52.0	54.0	23.5	19.1	
Total Operating Expenditure	263.7	225.2	253.5	17.1	4.0	
EBITDA	108.3	101.0	105.6	7.3	2.6	
EBITDA (%)	29.1	31.0	29.4	-184 bps	-29 bps	EBITDA margins declined 184 bps YoY to 29.1% while EBITDA grew 7.3% YoY to ₹ 108.3 crore
Interest	0.4	0.1	0.1	157.1	157.1	
Depreciation	11.4	11.7	11.5	-2.3	-0.3	
Other income	14.2	9.5	16.5	48.3	-14.1	
PBT before EO	110.7	98.7	110.5	12.2	0.2	
Less: Exceptional Items	0.0	0.0	0.0	0.0	0.0	
PBT	110.7	98.7	110.5	12.2	0.2	
Tax	14.4	19.4	18.4	-26.0	-22.1	
MI & Share of loss/ (gain) asso.	-0.1	4.3	0.4	PL	PL	
Adjusted Net Profit	96.4	75.0	91.7	28.6	5.1	Adjusted PAT grew 28.6% YoY to ₹ 96.4 crore
Key Metrics						
LaTAm & Africa	319.9	300.0	297.4	6.6	7.6	
US	52.1	26.2	61.7	98.8	-15.6	

Source: Company, ICICI Direct Research

Exhibit 2: Change in estimates

(₹ Crore)	FY23E			FY24E			Comments
	Old	New	Change	Old	New	Change	
Revenue	1,471.3	1,456.9	-1.0	1,703.2	1,659.0	-2.6	
EBITDA	435.6	429.0	-1.5	515.2	493.6	-4.2	
EBITDA Margin (%)	29.6	29.4	-16 bps	30.3	29.8	-50 bps	
PAT	371.5	371.1	-0.1	402.9	363.7	-9.7	
EPS (₹)	49.0	48.8	-0.4	53.2	47.9	-10.0	Changed due to higher tax assumptions

Source: ICICI Direct Research

Exhibit 3: Financial Summary

	Revenues	Growth	EPS	Growth	P/E	EV/EBITDA	RoE	RoCE
	(₹ crore)	(%)	(₹)	(%)	(x)	(X)	(%)	(%)
FY21	1061	22.9	31.9	12.6	22.0	14.8	20.4	25.4
FY22	1269	19.6	39.5	23.8	17.7	12.2	20.2	25.3
FY23E	1457	14.8	48.8	23.8	14.3	10.9	20.2	23.5
FY24E	1659	13.9	47.9	-2.0	14.6	9.2	16.7	22.4
FY25E	1865	12.4	54.1	13.1	12.9	7.5	16.0	21.6

Source: ICICI Direct Research

Exhibit 4: Trends in Quarterly Performance

(₹ crore)	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	YoY (%)	QoQ (%)
Total Operating Incom	228.2	215.2	240.1	268.1	274.4	278.7	300.4	303.5	326.2	339.2	346.3	359.1	372.0	14.0	3.6
Raw Material Expen	107.1	111.4	108.8	120.4	123.9	118.7	136.0	125.8	143.8	151.9	157.2	165.5	163.9	13.9	-1.0
% of Revenue	46.9	51.8	45.3	44.9	45.2	42.6	45.3	41.4	44.1	44.8	45.4	46.1	44.1	-4 bps	-203 bps
Gross Profit	121.1	103.8	131.3	147.8	150.5	160.0	164.5	177.8	182.4	187.3	189.1	193.6	208.1	14.1	7.5
Gross Profit Margin	53.1	48.2	54.7	55.1	54.8	57.4	54.7	58.6	55.9	55.2	54.6	53.9	55.9	4 bps	203 bps
Employee Expenses	17.7	18.5	25.9	25.3	25.5	25.9	26.7	29.0	29.4	30.2	32.4	34.0	35.5	21.0	4.5
% of Revenue	7.7	8.6	10.8	9.4	9.3	9.3	8.9	9.5	9.0	8.9	9.4	9.5	9.6	55 bps	8 bps
Other Expenditure	35.6	31.5	33.8	35.1	41.1	48.5	45.2	47.6	52.0	57.1	54.5	54.0	64.3	23.5	19.1
% of Revenue	15.6	14.6	14.1	13.1	15.0	17.4	15.0	15.7	15.9	16.8	15.7	15.0	17.3	133 bps	224 bps
Total Expenditure	160.4	161.4	168.5	180.7	190.5	193.0	207.8	202.4	225.2	239.3	244.2	253.5	263.7	17.1	4.0
% of Revenue	70.3	75.0	70.2	67.4	69.4	69.3	69.2	66.7	69.0	70.5	70.5	70.6	70.9	184 bps	29 bps
EBITDA	67.8	53.8	71.6	87.4	83.9	85.7	92.6	101.2	101.0	99.9	102.2	105.6	108.3	7.3	2.6
EBITDA Margin (%)	29.7	25.0	29.8	32.6	30.6	30.7	30.8	33.3	31.0	29.5	29.5	29.4	29.1	-184 bps	-29 bps
Other Income	10.3	19.6	6.5	1.8	5.8	9.5	9.2	8.5	9.5	11.5	13.9	16.5	14.2	48.3	-14.1
Interest	0.1	0.2	0.5	0.5	0.3	0.3	0.3	0.2	0.1	0.1	0.1	0.1	0.4	157.1	157.1
Depreciation	8.4	8.4	9.0	8.9	9.3	9.9	12.0	11.7	11.7	11.5	11.0	11.5	11.4	-2.3	-0.3
PBT	69.6	64.9	68.6	79.8	80.2	85.0	89.5	97.7	98.7	99.9	105.1	110.5	110.7	12.2	0.2
Total Tax	10.7	16.0	14.1	17.0	14.1	17.1	18.0	20.9	19.4	19.1	18.8	18.4	14.4	-26.0	-22.1
Tax rate (%)	15.4	24.7	20.5	21.3	17.5	20.1	20.1	21.4	19.6	19.1	17.9	16.7	13.0	-668 bps	-371 bps
PAT	58.6	48.9	54.5	56.9	64.5	66.4	70.9	75.0	75.0	79.1	85.0	91.7	96.4	28.6	5.1
PAT Margin (%)	25.7	22.7	22.7	21.2	23.5	23.8	23.6	24.7	23.0	23.3	24.5	25.5	25.9	294 bps	38 bps


Source: ICICI Direct Research

Exhibit 5: PE Band




Source: ICICI Direct Research

Exhibit 6: Revenues to grow at ~13.1% CAGR in FY23E-25E




Source: Company, ICICI Direct Research

Exhibit 7: EBITDA & EBITDA margins trend




Source: Company, ICICI Direct Research

Exhibit 8: PAT & PAT margins trend



Source: Company, ICICI Direct Research

Exhibit 9: RoE & RoCE trend



Source: Company, ICICI Direct Research

Financial Summary

Exhibit 10: Profit and loss statement		₹ crore			
(Year-end March)	FY22	FY23E	FY24E	FY25E	
Total Operating Income	1,269.4	1,456.9	1,659.0	1,865.3	
Growth (%)	19.6	14.8	13.9	12.4	
Raw Material Expenses	557.5	657.4	746.6	830.0	
Gross Profit	711.9	799.5	912.5	1,035.2	
Gross Profit Margins (%)	56.1	54.9	55.0	55.5	
Employee Expenses	115.3	137.1	153.5	172.5	
Other Expenditure	201.9	233.4	265.4	298.4	
Total Operating Expenditure	874.7	1,027.9	1,165.4	1,301.0	
EBITDA	394.7	429.0	493.6	564.2	
Growth (%)	20.1	8.7	15.1	14.3	
Interest	0.7	0.9	0.9	0.9	
Depreciation	46.9	45.3	62.4	76.4	
Other Income	38.8	59.0	67.2	75.5	
PBT before Exceptional Item	385.8	441.8	497.4	562.5	
Less: Exceptional Items	0.0	0.0	0.0	0.0	
PBT after Exceptional Items	385.8	441.8	497.4	562.5	
Total Tax	77.4	66.5	124.4	140.6	
PAT before MI	308.5	375.2	373.1	421.9	
Minority Interest	8.6	4.1	9.3	10.5	
PAT	299.8	371.1	363.7	411.3	
Growth (%)	23.8	23.8	-2.0	13.1	
EPS (Adjusted)	39.5	48.8	47.9	54.1	

Source: Company, ICICI Direct Research

Exhibit 11: Cash flow statement		₹ crore			
(Year-end March)	FY22	FY23E	FY24E	FY25E	
Profit/(Loss) after taxation	304.3	371.1	363.7	411.3	
Add: Depreciation & Amortization	46.9	45.3	62.4	76.4	
Net Increase in Current Assets	-96.0	-99.8	-99.7	-99.0	
Net Increase in Current Liabilities	97.9	31.4	28.4	26.8	
Others	-16.5	0.9	0.9	0.9	
CF from Operating activities	336.8	349.0	355.8	416.4	
(Purchase)/Sale of Fixed Assets	-91.2	-200.0	-200.0	-100.0	
Investments	-76.5	0.0	0.0	0.0	
Others	-124.9	-1.1	-1.1	-1.1	
CF from Investing activities	-292.6	-201.1	-201.1	-101.1	
Proceeds from Preference shares	-0.8	0.0	0.0	0.0	
(inc)/Dec in Loan	-16.6	0.0	0.0	0.0	
Dividend & Dividend tax	-22.7	-19.0	-22.8	-22.8	
Other	-0.7	-0.9	-0.9	-0.9	
CF from Financing activities	-40.7	-19.9	-23.7	-23.7	
Net Cash Flow	3.4	128.0	131.0	291.7	
Cash and Cash Equivalent	459.6	463.0	591.0	722.0	
Cash	463.0	591.0	722.0	1,013.6	
Free Cash Flow	245.6	149.0	155.8	316.4	

Source: Company, ICICI Direct Research

Exhibit 12: Balance Sheet		₹ crore			
(Year-end March)	FY22	FY23E	FY24E	FY25E	
Equity Capital	15.2	15.2	15.2	15.2	
Reserve and Surplus	1,468.8	1,820.9	2,161.8	2,550.3	
Total Shareholders funds	1,483.9	1,836.1	2,177.0	2,565.5	
Total Debt	2.1	2.1	2.1	2.1	
Minority Interest	26.0	26.0	26.0	26.0	
Deferred Tax Liability	0.0	0.0	0.0	0.0	
Other Non Current Liabilities	17.6	18.5	19.4	20.4	
Source of Funds	1,529.6	1,882.6	2,224.5	2,614.0	
Gross Block - Fixed Assets	450.6	630.6	845.6	960.6	
Accumulated Depreciation	164.1	209.4	271.8	348.2	
Net Block	286.6	421.3	573.9	612.5	
Capital WIP	17.7	37.7	22.7	7.7	
Fixed Assets	304.3	459.0	596.6	620.2	
Investments	89.0	89.0	89.0	89.0	
Other non-Current Assets	97.2	99.1	101.1	103.1	
Inventory	227.3	268.0	304.4	338.4	
Debtors	320.1	367.3	418.3	470.3	
ST Loans and Advances	0.0	0.0	0.0	0.0	
Other Current Assets	235.5	247.3	259.6	272.6	
Cash	463.0	591.0	722.0	1,013.6	
Total Current Assets	1,245.9	1,473.6	1,704.3	2,095.0	
Creditors	163.2	192.4	218.5	243.0	
Provisions	2.6	2.7	2.8	3.0	
Other Current Liabilities	41.0	43.0	45.2	47.4	
Total Current Liabilities	206.7	238.1	266.5	293.4	
Net Current Assets	1,039.1	1,235.5	1,437.8	1,801.6	
Application of Funds	1,529.6	1,882.6	2,224.5	2,614.0	

Source: Company, ICICI Direct Research

Exhibit 13: Key ratios					
(Year-end March)	FY22	FY23E	FY24E	FY25E	
Per share data (₹)					
Reported EPS	39.5	48.8	47.9	54.1	
Cash EPS	41.6	52.3	53.1	61.2	
BV per share	195.3	241.6	286.4	337.6	
Cash per Share	60.9	77.8	95.0	133.4	
Dividend per share	4.0	2.5	3.0	3.0	
Operating Ratios (%)					
Gross Profit Margins	56.1	54.9	55.0	55.5	
EBITDA margins	31.1	29.4	29.8	30.3	
PAT Margins	23.6	25.5	21.9	22.1	
Cash Conversion Cycle	134.0	134.0	134.0	134.0	
Asset Turnover	2.8	2.3	2.0	1.9	
EBITDA conversion Rate	85.3	81.4	72.1	73.8	
Return Ratios (%)					
RoE	20.2	20.2	16.7	16.0	
RoCE	25.3	23.5	22.4	21.6	
RoIC	34.9	31.9	30.2	31.7	
Valuation Ratios (x)					
P/E	17.7	14.3	14.6	12.9	
EV / EBITDA	12.2	10.9	9.2	7.5	
EV / Net Sales	3.8	3.2	2.7	2.3	
Market Cap / Sales	4.2	3.7	3.2	2.9	
Price to Book Value	3.6	2.9	2.4	2.1	
Solvency Ratios					
Debt / EBITDA	0.0	0.0	0.0	0.0	
Debt / Equity	0.0	0.0	0.0	0.0	
Current Ratio	3.8	3.7	3.7	3.7	
Quick Ratio					
Inventory days	2.7	2.6	2.5	2.5	
Debtor days	148.8	148.8	148.8	148.8	
Creditor days	92.0	92.0	92.0	92.0	
Creditor days	106.8	106.8	106.8	106.8	

Source: Company, ICICI Direct Research

Exhibit 14: ICICI Direct Coverage Universe (Healthcare)

Company	I-Direct Code	CMP (₹)	TP (₹)	Rating	M Cap (₹ cr)	EPS (₹)				EV/EBITDA(x)				RoCE (%)			RoE (%)				
						FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E
Hospitals																					
Apollo Hospitals	APOHOS	4330	5,230	Buy	62259	7.8	59.1	67.8	85.2	57.7	29.8	29.3	24.6	6.3	15.1	14.7	16.7	2.5	15.1	15.2	16.6
Narayana Hrudalaya	NARHRU	721	870	Buy	14735	-0.7	16.7	28.8	28.9	86.0	23.8	18.1	16.4	1.2	20.5	24.2	21.0	-1.3	23.0	28.6	22.5
Shalby	SHALUM	138	180	Buy	1492	3.9	5.4	6.9	9.5	17.6	13.3	9.4	7.2	6.5	8.4	11.5	13.9	5.1	6.7	8.0	10.1
Aster DM	ASTDM	208	300	Buy	10410	3.0	10.5	8.1	18.5	16.0	11.5	10.6	7.2	5.4	9.0	9.1	14.0	4.4	13.3	9.3	17.5
Healthcare Global	HEAGLO	272	385	Buy	3786	-13.9	3.9	2.2	6.0	39.4	20.1	14.9	12.0	-0.9	5.0	8.7	12.7	-0.9	5.0	3.4	8.4
Company																					
Company	I-Direct Code	CMP (₹)	TP (₹)	Rating	M Cap (₹ cr)	EPS (₹)				PE(x)				RoCE (%)			RoE (%)				
						FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E	FY21	FY22	FY23E	FY24E
MNC Pharma																					
Abbott India	ABBIND	20135	21,025	Hold	44328	328.9	380.3	476.5	519.3	61.2	52.9	42.3	38.8	33.8	36.6	39.7	35.6	26.5	28.3	30.9	27.5
P&G Health	MERLUM	4691	5,315	Buy	7787	106.5	116.0	150.0	163.6	44.0	40.4	31.3	28.7	32.2	39.8	42.5	38.0	25.1	31.2	32.0	28.5
Sanofi India	SANOFI	5360	6,385	Hold	12344	207.7	410.6	266.3	255.8	25.8	13.1	20.1	21.0	32.3	33.3	40.9	50.2	24.5	25.9	30.8	38.1
Pfizer	PFIZER	3833	4,505	Hold	17536	108.8	133.2	150.5	149.3	35.2	28.8	25.5	25.7	27.6	26.1	25.0	23.7	20.8	21.4	18.8	18.2
Pharma																					
Ajanta Pharma	AJAPHA	1210	1,385	Buy	15510	51.1	55.7	51.2	67.9	23.7	21.7	23.6	17.8	29.0	27.0	21.5	24.3	21.8	21.8	17.5	19.7
Alembic Pharma	ALEMPHA	516	550	Hold	10140	62.6	27.7	15.3	23.2	8.2	18.6	33.7	22.2	25.1	10.6	7.1	9.8	24.1	10.4	5.6	8.0
Aurobindo Pharma	AURPHA	472	525	Hold	27665	55.0	47.4	34.8	46.2	8.6	10.0	13.5	10.2	16.9	12.9	10.2	12.6	14.7	11.3	7.7	9.3
Biocon	BIOCON	238	290	Hold	28538	6.3	4.9	3.0	5.3	38.0	48.2	78.2	45.2	7.7	7.5	3.8	6.1	9.9	8.1	1.5	2.4
Zydus Lifesciences	CADHEA	469	500	Buy	47467	23.3	21.0	22.6	27.0	20.1	22.3	20.8	17.4	13.8	12.0	12.3	12.3	18.4	12.6	12.1	12.8
Cipla	CIPLA	1021	1,290	Buy	82409	29.9	32.9	38.3	45.5	34.1	31.0	26.7	22.4	17.0	16.7	18.4	19.1	13.1	12.7	13.3	14.1
Dr Reddy's Labs	DRREDD	4515	5,210	Buy	75191	117.6	127.2	262.2	215.5	38.4	35.5	17.2	21.0	13.1	13.0	24.2	20.8	11.1	11.0	18.9	13.8
Glenmark Pharma	GLEPHA	401	440	Hold	11879	32.9	42.7	33.3	47.4	12.2	9.4	12.1	8.5	13.9	14.8	14.9	15.7	13.1	13.2	9.4	11.9
Ipca Laboratories	IPCLAB	859	925	Hold	21792	44.9	34.8	24.5	35.7	19.1	24.7	35.1	24.1	27.1	17.4	13.3	16.5	24.2	16.1	10.3	13.3
Jubilant Pharmova	JUBLIF	319	395	Hold	5088	37.4	26.0	22.5	32.8	8.5	12.3	14.2	9.7	13.7	9.0	7.8	9.7	12.6	7.8	6.4	8.6
Lupin	LUPIN	675	725	Hold	30709	26.9	11.9	8.3	25.6	25.1	56.8	81.2	26.3	9.6	3.4	5.7	11.0	8.8	4.4	3.0	8.6
Natco Pharma	NATPHA	535	660	Hold	9765	24.2	9.3	38.6	46.3	22.2	57.5	13.9	11.6	13.1	4.6	16.8	18.5	10.7	4.0	14.6	15.2
Sun Pharma	SUNPHA	1015	1,210	Buy	243407	30.1	32.0	34.9	38.6	33.8	31.8	29.1	26.3	14.2	18.2	17.2	18.1	15.5	16.0	15.2	14.7
Torrent Pharma	TORPHA	1515	1,720	Hold	51274	37.0	32.0	36.3	45.1	41.0	47.3	41.7	33.6	17.6	19.7	17.1	20.4	21.4	18.2	17.9	19.0
Indoco Remedies	INDREM	367	440	Buy	3380	10.1	16.8	17.9	26.7	36.3	21.8	20.4	13.7	11.7	17.5	15.6	21.9	12.1	17.1	15.9	19.8
Caplin Point	CAPPOI	700	865	Buy	5323	31.9	39.5	48.8	47.9	22.0	17.7	14.3	14.6	25.4	25.3	23.5	22.4	20.4	20.2	20.2	16.7
Advanced Enzymes	ADVENZ	273	265	Reduce	3056	13.1	10.7	9.6	13.3	20.9	25.5	28.6	20.5	19.4	14.3	10.9	14.0	15.1	11.0	9.0	11.3
Hester Biosciences	HESPHA	1788	1,830	Hold	1521	44.4	45.7	35.6	49.7	40.3	39.1	50.2	36.0	16.2	10.9	9.9	10.9	16.5	15.0	10.7	13.5
API/CRAMS																					
Divi's Lab	DIVLAB	2770	2,945	Hold	73535	74.7	111.5	72.8	77.4	37.1	24.8	38.0	35.8	27.6	30.2	18.2	18.3	18.8	21.3	25.2	15.0
Hikal	HIKCHE	330	375	Hold	4064	10.8	13.0	5.7	14.6	30.6	25.3	58.0	22.7	15.1	13.6	7.2	14.3	14.3	15.0	6.3	14.1
Syngene Int.	SYNINT	562	610	Hold	22547	10.1	9.9	12.1	14.7	55.5	56.9	46.4	38.1	11.5	11.7	13.4	14.4	13.5	12.9	13.0	13.7
Granules India	GRANUL	285	355	Buy	7083	22.2	16.6	21.4	24.0	12.9	17.1	13.3	11.9	24.0	15.6	20.0	20.5	25.3	16.0	18.7	17.6
Laurus Labs	LAULAB	333	400	Buy	17926	18.3	15.4	16.5	19.1	18.2	21.6	20.1	17.4	31.7	21.3	21.8	21.5	37.9	24.7	21.4	20.2
Suven Pharmaceuticals	SUVPH	484	530	Buy	12318	14.2	17.8	14.7	17.7	34.0	27.2	32.8	27.4	31.2	37.5	26.0	25.6	30.7	29.7	20.6	20.5

Source: ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

**ICICI Direct Research Desk,
ICICI Securities Limited,
1st Floor, Akruiti Trade Centre,
Road No 7, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com**

ANALYST CERTIFICATION

I/We, Siddhant Khandekar - Inter CA, Kushal Shah - CFA L1, CFP, Utkarsh Jain - MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.